RRC ID 60551
著者 Kunishima H, Ishibashi N, Wada K, Oka K, Takahashi M, Yamasaki Y, Aoyagi T, Takemura H, Kitagawa M, Kaku M.
タイトル The effect of gut microbiota and probiotic organisms on the properties of extended spectrum beta-lactamase producing and carbapenem resistant Enterobacteriaceae including growth, beta-lactamase activity and gene transmissibility.
ジャーナル J Infect Chemother
Abstract The gut microbiota may play a pivotal role in controlling the antimicrobial resistant (AMR) organisms although the evidences are limited. We investigated the effects of gut microbiota on the growth of AMR organisms, β-lactamases activity and transmissibility of antimicrobial resistant properties of the extended spectrum β-lactamase (ESBL)-producing Escherichia coli and carbapenem-resistant Enterobacteriaceae. CTX-M-15-positive, ESBL-producing E. coli and carbapenem resistant Enterobacteriaceae, Bacteroides fragilis, Bifidobacterium longum, Clostridium butyricum, Clostridioides difficile, Clostridium perfringens, Enterococcus faecium, Lactobacillus plantarum and probiotic strain of C. butyricum MIYAIRI 588 were used in this study. The growth of AMR organisms was suppressed by the supernatant of C. butyricum, C. difficile, C. perfringens, E. faecium and L. plantarum in a dose dependent manner but not by that of B. fragilis and B. longum. The β-lactamase activity produced by E. coli was reduced by the presence of culture supernatant of certain gut microbiota during stationary phase of E. coli. Importantly, C. butyricum MIYAIRI 588 culture supernatant suppressed the transcription of blaCTX-M gene during growth phase of E. coli. The conjugation assay showed the reduction of transmissibility of antibiotic resistant gene by gut microbiota. These findings suggest that certain gut microbiota affect the antibiotic resistant activities of AMR organisms. Further studies are needed to identify the specific mechanism(s) of these actions between AMR organisms and gut microbiota.
巻・号 25(11)
ページ 894-900
公開日 2019-11-1
DOI 10.1016/j.jiac.2019.04.021
PII S1341-321X(19)30134-5
PMID 31178280
MeSH Anti-Bacterial Agents / therapeutic use* Carbapenem-Resistant Enterobacteriaceae / drug effects* Carbapenems / therapeutic use* Enterobacteriaceae Infections / drug therapy* Enterobacteriaceae Infections / microbiology Gastrointestinal Microbiome / physiology* Humans Microbial Sensitivity Tests / methods Probiotics / therapeutic use* beta-Lactamases / metabolism*
IF 1.539
引用数 1
リソース情報
一般微生物 JCM1217 JCM1290 JCM5804 JCM1149